Drug intelligence / Profile preview

Virella SIRT6 activator

Development stage: Preclinical
Lead developer: Virella
Modality: Small Molecules

Overview

Virella's SIRT6 activator is a preclinical small molecule candidate developed by Virella Science, utilizing a novel griseofulvin-based chemical scaffold platform. The drug is designed to activate Sirtuin 6 (SIRT6), a NAD+-dependent deacetylase that serves as a key regulator of metabolic processes, DNA repair, and genomic stability. By enhancing SIRT6 activity, the molecule aims to restore glucose homeostasis and improve lipid metabolism, targeting indications such as metabolic disease and associated dysfunctions. The program is currently in the preclinical stage of development, leveraging Virella's proprietary chemical scaffolds to address unmet needs in metabolic health.

Other names: SIRT6 activator (Virella Science)

Targets

SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on Virella SIRT6 activator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virella SIRT6 activator.

Explore the full profile